"10.1371_journal.pone.0061128","plos one","2013-04-08T00:00:00Z","Lena Muchnik; Asad Adawi; Ariel Ohayon; Shahar Dotan; Itai Malka; Shalhevet Azriel; Marilou Shagan; Maxim Portnoi; Daniel Kafka; Hannie Nahmani; Angel Porgador; Johnatan M Gershoni; Donald A Morrison; Andrea Mitchell; Michael Tal; Ronald Ellis; Ron Dagan; Yaffa Mizrachi Nebenzahl","Pediatric Infectious Disease Unit, Soroka University Medical Center, Beer Sheva, Israel; The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; Protea Vaccine Technologies and NasVax Ltd., Ness Ziona, Israel; Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel; Department of Biological Sciences, University of Illinois at Chicago, Chicago, Illinois, United States of America; School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, United Kingdom","Conceived and designed the experiments: YMN RD RE MT DAM JMG AO SD AP. Performed the experiments: LM AO SD SA IM MS MP DK AA HN AP. Analyzed the data: AO SD. Contributed reagents/materials/analysis tools: JMG AM. Wrote the paper: YMN AO SD.","The study and part of the authors were partially funded by a commercial company (Nasvax Ltd./Protea Vaccine Technologies Ltd.) through the BGNegev Biotechnologies which is the BGU industrial liaison. Nasvax Ltd./Protea Vaccine Technologies Ltd. is the employer of authors Shahar Dotan, Michael Tal and Ronald Ellis. The NOX protein discussed in the enclosed manuscript is protected by several pending patents: US WO 03/082183; EP 1490104; PCT WO 2010/029546 A2. The protein vaccine is at an early stage of preclinical studies. There are no marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","04","Lena Muchnik","LM",18,TRUE,9,11,2,3,TRUE,FALSE,FALSE,0,NA,FALSE
